TYP — Material Events
ASX:TYP · 4 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Tryp Secures $6.1m to Accelerate Psilocin Drug Trials for Binge Eating DisorderMedium
Tryptamine Therapeutics raises $6.1m to fast-track TRP-8803 clinical development
5 Nov 2025
·Capital Raising
·85
Tryptamine Therapeutics Launches World-First Trial for Binge Eating DisorderMedium
Tryptamine Therapeutics advances TRP-8803 BED trial, secures funding and landmark biomarker collaboration
31 Oct 2025
·Quarterly Activities Report
·85
Tryptamine Therapeutics Enrolls First Patient in Groundbreaking BED TrialMedium
Tryptamine Therapeutics Enrolls First Patient in Pioneering IV Psilocin Trial for Binge Eating Disorder
14 Oct 2025
·Clinical Trial Update
·85
No articles in this tier for the last 12 months.